Core Viewpoint - The strategic cooperation agreement signed between LianKang Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and the Ouhai District People's Government aims to enhance the group's research and development pipeline in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating the implementation of its strategic goals [1][2]. Group 1 - The collaboration will leverage the strengths of each party in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical transformation and industrialization in the application of growth factor drugs in regenerative medicine [1][2]. - The parties will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, with the aim of developing new compound formulations and delivery systems [1][2]. - This partnership is expected to fill treatment gaps in various specific indications and further unlock clinical and commercial value in the extensive chronic disease market [1]. Group 2 - The Wenzhou Medical University National Engineering Research Center, led by Academician Li Xiaokun of the Chinese Academy of Engineering, is a leading independent entity in the field of growth factor drugs, focusing on basic research and new drug development [2]. - The Ouhai District People's Government plays a crucial role in supporting this strategic cooperation, aiming to create a top-tier biopharmaceutical industry ecosystem, providing comprehensive support and policy backing for the collaboration project [2]. - This cooperation is anticipated to enhance the group's research efficiency and success rate in the field of biopharmaceutical innovation, shorten product development cycles, and strengthen its competitive edge in the EGF/FGF segment [2].
联康生物科技集团(00690.HK)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作